COPD's early origins in low-and-middle income countries

Brakema, E. A.; van Gemert, F. A.; van der Kleij, R. M. J. J.; Salvi, S.; Puhan, M.; Chavannes, N. H.; Pham Le An; Anastasaki, Marilena; Akmatalieva, Meerim; Akylbekov, Azamat; Barton, Andy; Bertsias, Antonios; Pham Duong Uyen Binh; van Boven, Job F. M.; Burges, Dennis; Cartwright, Lucy; Chatzea, Vasiliki E.; Cragg, Liza; Tran Ngoc Dang; Dautov, Ilyas; Emilov, Berik; Ferarrio, Irene; Hedrick, Ben; Le Huynh Thi Cam Hong; Hopkinson, Nick; Isaeva, Elvira; Jones, Rupert; de Jong, Corina; van Kampen, Sanne; Katagira, Winceslaus; Kirenga, Bruce; Kjærgaard, Jesper; Kocks, Janwillem; Le Thi Tuyet Lan; Tran Thanh Duy Linh; Lionis, Christos; Kim Xuan Loan; Mademilov, Maamed; McEwen, Andy; Musinguzi, Patrick; Nantanda, Rebecca; Ndeezi, Grace; Papadakis, Sophia; Pinnock, Hilary; Pooler, Jillian; Poot, Charlotte; Postma, Maarten J.; Poulsen, Anja; Powell, Pippa; Nguyen Nhat Quynh; Reventlow, Susanne; Sifaki-Pistolla, Dimitra; Singh, Sally; Sooronbaev, Talant; de Sousa, Jaime Correia; Stout, James; Stubbe-Østergaard, Marianne; Tabyshova, Aizhamal; Tsiligianni, Ioanna; Tran Diep Tuan; Tumwine, James; Le Thanh Van; Nguyen Nhu Vinh; Walusimbi, Simon; Warren, Louise; Williams, Sian

Published in: npj Primary Care Respiratory Medicine

DOI: 10.1038/s41533-019-0117-y

Publication date: 2019

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
COPD’s early origins in low-and-middle income countries: what are the implications of a false start?

E. A. Brakema1, F. A. van Gemert2, R. M. J. J. van der Kleij1, S. Salvi3, M. Puhan4, N. H. Chavannes5 and the FRESH AIR collaborators

npj Primary Care Respiratory Medicine (2019) 29:6; https://doi.org/10.1038/s41533-019-0117-y

The Global Initiative for chronic Obstructive Lung disease (GOLD) guideline of 2018 describes COPD as ‘the result of a complex interplay of long-term cumulative exposure to noxious gases and particles, combined with a variety of host factors including genetics, airway hyper-responsiveness and poor lung growth during childhood’.1 Tobacco smoking is traditionally viewed as the main contributing factor to the development of COPD. However, COPD also occurs among non-smokers, especially in low-income and middle-income countries (LMICs).2,3 Notably, more than 90% of COPD-related deaths occur in LMICs.4 For these countries, other risk factors, such as ambient, occupational and household air pollution play a significant role in the development of COPD.1,2,5–7

Does COPD in these settings have a different pathophysiological trajectory compared to COPD in high-income countries, and if so: what does this imply?

In normal lung development, airway branching is completed by the 17th week of gestation, after which airways increase in volume until young adulthood. Alveoli are present at birth and develop further during childhood. Lung volume and airflow continue to increase as the thorax grows, influenced by age, sex, and ethnicity, reaching a peak at young adulthood. Lung function then remains constant for about 10 years (the plateau phase), after which it gradually declines.8 In the ‘classic’ COPD patient, the decline in lung function is more rapid than in healthy individuals. However, in a considerable proportion of COPD patients, lung function does not decline rapidly, but reaches a lower plateau phase in early adulthood instead. For these patients, a completely different pathophysiological trajectory seems to lead to the diagnosis of COPD: the decline in lung function follows a normal pattern, yet they seem to have a ‘false start’ by attaining a lower maximum lung function.8–11

Several factors can contribute to a lower maximum lung function. There is increasing evidence that different environmental factors (such as tobacco smoke, household air pollution caused by burning solid fuels or kerosene lamps), maternal factors (malnutrition, asthma, diabetes), and gene–environment interactions can impact lung growth. Additionally, childhood factors (low birth weight, prematurity) and other diseases during childhood (lower respiratory tract infections, asthma, tuberculosis, HIV) may all contribute to a decline in lung function.1,3,5,6,9,11–14 (Mal) nutrition additionally plays a vital role in lung development.15 Unfortunately, many of these factors commonly interrelate and co-occur in LMICs. A low socioeconomic status can furthermore deteriorate the situation, as this is not only independently associated with a lower lung function, but also with other health risks (poor access to healthcare, poor nutrition, low birth weight, exposure to indoor and outdoor pollution, poor living conditions and water supply/sanitation).16–18 Overall, populations in LMICs are particularly vulnerable to such risk factors for a lower maximum lung function.16,18

Our knowledge about reduced maximum attained lung functions caused by ‘early life disadvantage factors’ in LMICs seems humble compared to the knowledge generated by extensive research on tobacco-related COPD, often conducted in high-income countries.5,9,13,19 The question is whether these early life, disadvantageous factors cause different COPD phenotypes with their own pathophysiology, diagnostic approach, rate of lung function decline, response to treatment, and potential reversibility.3,9,13,19 The paucity of data indicates differences may exist, and that those with a lower forced expiratory volume in one second in early adulthood are also exposed to an increased prevalence and earlier incidence of other non-communicable diseases and premature death.5,12,20,21 Additionally, COPD related to biomass fuel smoke was demonstrated to be commonly present among young, non-smoking women,6 whereas ‘classic’ COPD patients are elderly, smoking men. Such difference could be attributed to differences in risk exposure between men and women, yet potential differences in sensitivity to COPD between men and women per phenotype could play an additional role. Furthermore, as rates of lung function decline vary according to sex and that those with a lower plateau phase seem harder to influence. COPD caused by a false start has several implications. First, COPD caused by early life disadvantage factors should be tackled at much earlier stages. Prevention is key, and must start before birth, continue throughout childhood and then be combined with the ‘regular’ preventive measures targeting an accelerated decline. As early life disadvantage factors are diverse, prevention addressing these factors should be equally diverse. We argue that raising awareness on COPD is therefore crucial. COPD, the third cause of death worldwide, is often completely unknown to local community members, including their healthcare professionals and policy makers.22 Local curricula for healthcare professionals (doctors,
Increased awareness on the early development of COPD and on the existence of COPD in general could enhance early diagnosis and timely action. Increased awareness is particularly important considering the widespread underdiagnosis of COPD. This raises the question how to best diagnose the disease (affordably, easy to learn), and how to do so at an early stage. Whether affordable medications to treat COPD in LMICs are rare, non-pharmacological approaches, such as pulmonary rehabilitation and patient education, can impact COPD symptoms and disease progression. Particularly in LMICs, these approaches seem cost-effective (if not, cost-saving).

The second implication is related to research. As outlined earlier, more research into a lower maximum lung function and its clinical implications is needed. Furthermore, a false start implies a different perspective on how to study the effect of interventions targeting household air pollution on lung function. For decades, clean cook stoves programmes fail to demonstrate consistent positive effects on lung function. Often this is attributed to flawed implementation of such interventions, or to cross-contamination of air pollution within the community. However, even after successful adoption of clean cook stoves, the lungs in this generation could remain irreversibly damaged. Instead, should we not measure effects on lung function among children and adolescents, or even among the next (unborn) generation?

To conclude, COPD development generally starts early in life due to a complex interplay of disadvantageous factors. Many of these factors particularly occur in LMICs. To address the silent growing epidemic of COPD in LMICs, lung health should be optimised even before birth and in early childhood. Prevention is key, and focus should be on creating large-scale awareness—beyond the healthcare system only, involving all stakeholders. More research is needed to explore the implications of early life disadvantage factors for COPD in LMICs. This should lead to an evidence-based approach for those with a false start—those (at risk of) having a lower maximum lung function.

FRESH AIR COLLABORATORS
Pham Le Anh, Marilena Anastasakos, Meerim Akmatalieva, Azamat Akylbekov, Andy Barton, Antonios Berttsias, Pham Duong Uyen Binh, Job F. M. van Boven, Dennis Burges, Lucy Cartwright, Vasiliki E. Chatzea, Liza Crigg, Tran Ngoc Dang, Ilyas Dautov, Berik Emilov, Irene Ferario, Ben Hedrick, Le Huynh Thi Cam Hong, Nick Hopkins, Elvira Iskova, Rupert Jones, Corina de Jong, Sophia Papadakis, Irene Ferario, Ben Hedrick, Le Huynh Thi Cam Hong, Nick Hopkins, Elvira Iskova, Rupert Jones, Corina de Jong, Sophia Papadakis, and Jillian Pooler.

AUTHOR CONTRIBUTIONS
E.A.B. wrote the first version and subsequent versions of this manuscript in close collaboration with F.v.G. R.v.d.K, M.P., S.S., and N.G. gave input throughout the entire process.

ADDITIONAL INFORMATION
Competing interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
21. Imperial College London, London, UK; 22Makerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda; 23The Research Unit for General Practice and Section of General Practice, Department of Public Health, Copenhagen University, Copenhagen, Denmark; 24Global Health Unit, The Department of Paediatrics and Adolescent Health, Juliane Marie Center, Copenhagen University Hospital “Righospitalet”, Copenhagen, Denmark; 25National Centre for Smoking Cessation and Training, Dorchester, UK; 26University of Edinburgh, Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK; 27Covenant University, Coventry, UK and 28University of Minho, School of Medicine, Braga, Portugal

13University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam; 14Clinic of Social and Family Medicine, School of Medicine, University of Crete, Heraklion, Greece; 15Ministry of Health of the Kyrgyz Republic, National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan; 16Faculty of Medicine and Dentistry, University of Plymouth, Plymouth, UK; 17University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 18Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA; 19International Primary Care Respiratory Group, London, UK; 20European Lung Foundation, Sheffield, UK.


